Last updated: October 1, 2026

Depakene is the brand name for valproic acid, an established antiseizure medicine marketed in a highly genericized market. Its commercial value is driven by low-cost generic volume rather than brand pricing power. The original product has no meaningful remaining market exclusivity, no material composition-patent protection, and limited standalone financial disclosure. Competitive pressure comes from generic valproic acid, divalproex sodium products such as Depakote and Depakote ER, and alternative antiseizure therapies.

What is Depakene and how is it used?

Depakene contains valproic acid. The FDA-approved product is used primarily for:

Complex partial seizures
Simple and complex absence seizures
Other seizure types as specified in labeling

Valproic acid is also used clinically across broader valproate therapy, including bipolar disorder and migraine prevention, although those uses may involve different products, labels, or off-label prescribing. Depakote contains divalproex sodium, a compound that dissociates to valproate in the gastrointestinal tract. Depakote and Depakene are pharmacologically related but are not interchangeable on a milligram-for-milligram basis without clinical direction.

The FDA-approved Depakene dosage forms include capsules and oral solution. The product is listed under New Drug Application 018081 in FDA records.[1]

What is the FDA and Orange Book status of Depakene?

Depakene is an old small-molecule product with FDA approval dating to the late 1970s. Its commercial status is materially different from that of a recently approved branded drug.

Product	Active ingredient	Dosage forms	FDA status	Market position
Depakene	Valproic acid	Capsules, oral solution	Approved legacy product	Originator brand with generic competition
Generic valproic acid	Valproic acid	Capsules, oral solution, other presentations	Multiple ANDA approvals	Primary low-cost competitor
Depakote	Divalproex sodium	Delayed-release tablets, sprinkle capsules	Approved	Related branded valproate product
Depakote ER	Divalproex sodium	Extended-release tablets	Approved	Extended-release alternative
Generic divalproex sodium	Divalproex sodium	Delayed-release and extended-release forms	Multiple ANDA approvals	Major substitute

The Orange Book framework provides little commercial protection for Depakene today. The product’s original regulatory exclusivity expired decades ago, and generic manufacturers have had extensive opportunity to file abbreviated new drug applications. Current Orange Book protection is not the primary factor governing market access for valproic acid.[2]

When did Depakene lose exclusivity?

Depakene lost meaningful market exclusivity many years ago. The product was approved before the modern Hatch-Waxman period generated the patent-and-exclusivity structures now associated with new branded medicines.

Milestone	Approximate timing	Commercial effect
Original FDA approval of Depakene	Late 1970s	Established the reference product
Original regulatory exclusivity	Expired decades ago	No current regulatory barrier
Generic valproic acid entry	Historical, with multiple suppliers	Eroded brand pricing
Current market	Mature generic market	Brand has limited negotiating leverage

A precise current “loss-of-exclusivity” date is not commercially meaningful because generic competition began long ago and the active ingredient has been available as an established therapy for decades.

What patents protect Depakene?

Depakene has no meaningful active patent estate protecting the valproic acid molecule. Valproic acid is an old compound, and the core commercial question is generic availability rather than patent validity.

The relevant protection profile is:

Protection category	Depakene position
Composition-of-matter patent	No meaningful current protection
Basic formulation patent	No material current barrier identified
Method-of-use patent	No material current barrier controlling ordinary seizure treatment
Pediatric exclusivity	Expired or not commercially relevant
Orphan-drug exclusivity	Not a current market barrier
Manufacturing patent	Potentially relevant to individual suppliers, not to market access
Orange Book patent protection	Not the primary constraint on generic entry

The distinction between Depakene and newer drugs is important. A newer antiseizure product may rely on formulation, delivery-system, crystal-form, or method-of-use patents. Depakene does not have a comparable modern patent structure.

How many patents cover Depakene?

No commercially significant patent portfolio currently blocks generic valproic acid. Patent counts can vary depending on whether expired, abandoned, manufacturing, process, foreign, or family-member patents are included. Those counts do not translate into effective exclusivity.

The relevant business conclusion is that Depakene has no defensible patent moat around its active ingredient, conventional capsules, or oral-solution presentations. Any supplier-specific manufacturing patents would be unlikely to prevent competing manufacturers from selling standard valproic acid through independent processes.

What generic entry risks exist for Depakene?

Generic entry risk is high because the product is already exposed to generic competition. The issue is not a future first generic launch; it is continuing price erosion, supplier substitution, and potential supply disruption.

Generic competition affects Depakene through:

Lower reimbursement benchmarks.
Pharmacy substitution under state and payer rules.
Multiple approved suppliers.
Formulary preference for generic valproic acid.
Limited patient willingness to pay for the branded product.
Procurement pressure from hospitals, Medicaid, Medicare Part D plans, and wholesalers.

The principal remaining commercial risks are manufacturing quality, supply continuity, recalls, and changes in payer contracting. A generic manufacturer does not need to overcome a strong patent barrier to enter or remain in the market.

What formulation patents protect Depakene capsules and oral solution?

Depakene’s conventional dosage forms do not have a commercially meaningful formulation moat. Capsules and oral solution are technically established products with well-understood manufacturing processes.

The formulation-related competitive issues are practical rather than patent-driven:

Assay and content uniformity
Stability of the oral solution
Taste and palatability
Packaging and dosing accuracy
Excipient compatibility
Control of impurities
Consistent bioavailability
Manufacturing-site qualification

Divalproex sodium products create a separate formulation market. Delayed-release and extended-release products use different release technologies and may have more complex manufacturing requirements. Those products compete with Depakene clinically but do not create patent protection for Depakene itself.

What FDA safety restrictions affect Depakene demand?

Valproate products carry substantial safety warnings that influence prescribing, patient selection, monitoring, and market growth.

The FDA labeling identifies risks including:

Fatal hepatotoxicity
Pancreatitis
Major congenital malformations
Neural-tube defects
Reduced fetal IQ and neurodevelopmental effects
Hyperammonemia
Thrombocytopenia
Drug interactions
Suicidal thoughts and behavior associated with antiepileptic drugs as a class

The FDA contraindicates valproic acid in certain patients with mitochondrial disorders involving POLG mutations and in specific urea-cycle disorders. The labeling also places strong restrictions on use during pregnancy and in women of childbearing potential when safer alternatives are appropriate.[3]

These warnings reduce the addressable market in some patient segments. They also support continued use in patients for whom valproate is clinically effective, particularly where seizure control is difficult and alternatives are unsuitable.

How does Depakene compare with Depakote and generic valproate?

Factor	Depakene	Depakote	Generic valproic acid
Active ingredient	Valproic acid	Divalproex sodium	Valproic acid
Primary role	Immediate-release valproate therapy	Delayed-release and other formulations	Low-cost substitute for valproic acid
Brand premium	Limited	Higher historical brand value	Minimal
Patent position	No meaningful current moat	Historical formulation and method-of-use protection, largely expired or eroded	No meaningful barrier
Payer position	Weak relative to generic	Depends on formulation and contract	Strong
Main differentiation	Familiar brand and dosage form	Release profile and product presentation	Price and availability
Commercial trajectory	Declining or stable at low level	Mature legacy brand	Persistent volume growth or retention

Depakote historically generated greater commercial value than Depakene because it supported differentiated delayed-release and extended-release products and broader commercial positioning. Depakene is more exposed to direct generic substitution.

What is the financial trajectory of Depakene?

AbbVie does not report Depakene as a separate revenue line in its public annual reports. The product is part of a legacy portfolio and is not identified as a material standalone contributor to consolidated revenue.[4]

The likely financial trajectory is:

Period	Financial condition
Early commercial period	Branded revenue supported by limited competition
Generic-entry period	Rapid price and share erosion
Mature-market period	Low-margin brand sales and generic substitution
Current market	Stable clinical demand but limited branded revenue visibility

The addressable clinical market remains substantial because epilepsy requires chronic treatment and valproate remains an established therapy. That does not translate into strong Depakene brand economics. Most economic value is captured through low-cost generic supply, institutional contracts, and broader valproate franchises rather than through the original Depakene label.

Revenue exposure for the brand is therefore likely immaterial relative to AbbVie’s major products. The principal value lies in residual prescription volume, brand recognition, manufacturing know-how, and portfolio continuity.

Which companies compete with Depakene?

Competition operates at two levels.

Direct valproic acid competitors

Multiple generic manufacturers have marketed valproic acid capsules or oral solution over time. The supplier base can change because of manufacturing economics, FDA compliance actions, product discontinuations, and wholesaler contracts. FDA’s approved-drug databases and Orange Book identify the relevant approved products and applicants.[2]

Therapeutic competitors

Depakene competes clinically with:

Levetiracetam
Lamotrigine
Carbamazepine
Oxcarbazepine
Topiramate
Phenytoin
Phenobarbital
Clobazam
Lacosamide
Zonisamide
Ethosuximide for selected absence-seizure patients

Competitive selection depends on seizure type, age, pregnancy risk, psychiatric comorbidity, drug interactions, hepatic function, renal function, dosing convenience, and cost.

Are companies challenging Depakene through Paragraph IV litigation?

Paragraph IV litigation is not a central current risk for Depakene. The product has been genericized for many years, and the absence of a meaningful active Orange Book patent estate leaves little basis for a conventional first-filer patent challenge against the original brand.

The relevant legal risks are different:

Product-liability claims involving fetal exposure
Failure-to-warn litigation
Manufacturing and quality disputes
Regulatory enforcement
Generic substitution and reimbursement disputes
Contract disputes involving supply or distribution

Valproate litigation has historically focused more heavily on alleged reproductive and developmental injuries than on patent infringement. Those liability matters can affect manufacturers, insurers, and settlement reserves, but they do not restore Depakene’s market exclusivity.

What patent litigation affects Depakene?

No material patent litigation is known to control current access to conventional Depakene capsules or oral solution. Patent disputes involving other valproate products, modified-release formulations, or unrelated antiseizure drugs should not be treated as Depakene-specific barriers.

The more relevant litigation exposure is product liability. Claims have alleged that valproate manufacturers inadequately warned about birth defects and neurodevelopmental risks. The financial impact varies by defendant, jurisdiction, settlement posture, and insurance coverage. It is separate from the commercial value of the Depakene brand.

Are there licensing deals for Depakene?

No major current licensing transaction is central to Depakene’s market position. The product’s commercial history traces to Abbott Laboratories and the later pharmaceutical operations of AbbVie. Corporate succession and portfolio transfers are more relevant than a recent external license.

A licensing transaction would have limited strategic value unless it provided:

Access to a lower-cost manufacturing network
Supply reliability
Geographic distribution rights
An improved formulation
A differentiated delivery system
A broader valproate portfolio

The conventional product itself has limited licensing leverage because generic alternatives are widely available.

What manufacturing and geographic barriers affect Depakene?

Manufacturing barriers are moderate at the operational level and low at the intellectual-property level.

A supplier must maintain:

FDA-compliant facilities
Validated analytical methods
Consistent active-ingredient sourcing
Stable formulation performance
Appropriate impurity controls
Reliable packaging and labeling
Adequate pharmacovigilance systems

Geographic coverage depends on national registrations, local manufacturing rules, tender systems, and reimbursement. A product approved in the United States does not automatically have equivalent market access in Europe, Japan, China, or emerging markets.

The global valproate market can therefore show regional supply shortages even when the underlying molecule is widely available. These shortages generally reflect manufacturing concentration, regulatory remediation, or procurement failures rather than patent restrictions.

What is the generic launch scenario for Depakene?

The generic launch scenario is already complete in the United States. The forward-looking commercial scenarios are:

Scenario	Market effect
Stable generic supply	Continued low prices and minimal brand growth
Generic manufacturer exit	Temporary price increases or regional shortages
FDA quality action	Supplier displacement and short-term volatility
Brand discontinuation	Generic substitution with limited clinical disruption
New valproate formulation	Possible niche competition, not a Depakene patent threat
Stronger pregnancy restrictions	Reduced use in selected patient groups

A future branded relaunch would require differentiation through delivery, adherence, pediatric usability, safety monitoring, or a new clinical indication. A standard valproic acid capsule or oral solution would face weak pricing prospects.

Key Takeaways

Depakene is an established valproic acid product with decades of generic competition.
Its original exclusivity expired long ago, and no meaningful active patent moat controls ordinary market access.
Generic valproic acid is the primary commercial competitor.
Depakote and Depakote ER compete through different valproate formulations and release profiles.
FDA safety warnings, especially reproductive and hepatic risks, constrain prescribing.
AbbVie does not separately disclose Depakene revenue, indicating limited standalone financial materiality.
The brand’s economics are driven by residual volume and portfolio continuity, not premium pricing.
Current business risks center on supply, quality, liability, and reimbursement rather than patent litigation.
The product has low generic-entry risk because generic entry is already established.
Any future value creation would require a differentiated formulation, delivery system, or new clinical positioning.

FAQs about Depakene market and patent status

Is Depakene still available in the United States?

Depakene remains an FDA-recognized valproic acid product, but practical availability can vary by dosage form, pharmacy inventory, wholesaler supply, and regional contracting. Generic valproic acid is more commonly used.

Is Depakene the same as divalproex sodium?

No. Depakene contains valproic acid. Depakote contains divalproex sodium, which produces valproate after administration. The products have related pharmacology but different chemical forms and release characteristics.

Can a generic manufacturer substitute valproic acid for Depakene?

Pharmacy substitution depends on the specific FDA-approved generic, dosage form, state law, payer rules, and prescriber instructions. Approved generic valproic acid products are intended to provide the same therapeutic ingredient and route of administration as the corresponding reference product.

Does Depakene have pediatric exclusivity?

No commercially relevant pediatric exclusivity protects the legacy product today. Any historical exclusivity period would have expired long ago.

What would increase the value of a new valproic acid product?

A new product would need meaningful differentiation, such as improved tolerability, reduced dosing frequency, better pediatric administration, a safer reproductive-risk profile, a delivery technology, or evidence supporting a defined underserved population. A conventional copy of Depakene would have limited commercial upside.

References

U.S. Food and Drug Administration. (n.d.). Depakene: Valproic acid, FDA drug label and approval information. Drugs@FDA.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.
U.S. Food and Drug Administration. (2024). Depakene prescribing information.
AbbVie Inc. (2024). Annual report for the fiscal year ended December 31, 2023.

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	119
Clinical Trials:	23
Patent Applications:	4,755
Drug Prices:	Drug price information for DEPAKENE
DailyMed Link:	DEPAKENE at DailyMed

Sponsor	Phase
Cancer Prevention Research Institute of Texas	Phase 2/Phase 3
M.D. Anderson Cancer Center	Phase 2/Phase 3
Kimberly S Jones	Phase 2

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	DEPAKENE	valproic acid	CAPSULE;ORAL	018081-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Abbvie	DEPAKENE	valproic acid	SYRUP;ORAL	018082-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

DEPAKENE Drug Patent Profile

Which patents cover Depakene, and when can generic versions of Depakene launch?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Depakene

AI Deep Research

Questions you can ask:

Summary for DEPAKENE

Recent Clinical Trials for DEPAKENE

US Patents and Regulatory Information for DEPAKENE

Depakene Market Dynamics, Patent Status, FDA Exclusivity, and Financial Trajectory